Product image
InVivoMAb anti-mouse CD40
BE0016-2
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-mouse CD40
- Delivery Days Customer7
- ApplicationsOther Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDFGK4.5/FGK45
- Concentration4-11 mg/ml
- HostRat
- IsotypeIgG2a
- Scientific DescriptionThe FGK4.5 monoclonal antibody reacts with mouse CD40 also known as Bp50. CD40 is a 48 kDa type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD40 is expressed broadly on antigen-presenting cells (APCs) such as dendritic cells, B cells, macrophages, and monocytes as well as non-immune endothelial cells, basal epithelial cells, and a range of tumors. Upon binding to its ligand CD154, CD40 acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other APCs. CD40 plays roles in B cell activation, differentiation, proliferation and Ig isotype switching as well as dendritic cell maturation. Agonistic CD40 monoclonal antibodies have been shown to activate APCs and promote anti-tumor T cell responses. The FGK4.5 antibody is an agonistic antibody that has been shown to activate CD40 expressing APCs. FGK4.5 can also be used to inhibit CD40/CD154 interaction in vitro and in vivo.
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Bauche D et al., 2018 Aug 21, ImmunityRead more
- Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8. Xu H et al., 2015 Dec, Nat ImmunolRead more
- Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T et al., 2015 Sep 22, Proc Natl Acad Sci U S ARead more
- DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Conde P et al., 2015 Jun 16, ImmunityRead more
- Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Carmi Y et al., 2015 May 7, NatureRead more
- Programmed death-1 impairs secondary effector lung CD8+ T cells during respiratory virus reinfection. Erickson JJ et al., 2014 Nov 15, J ImmunolRead more
- Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma. Muppidi JR et al., 2014 Dec 11, NatureRead more
- Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. Rabenstein H et al., 2014 Apr 15, J ImmunolRead more
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Hailemichael Y et al., 2013 Apr, Nat MedRead more
- Primary oligodendrocyte death does not elicit anti-CNS immunity. Locatelli G et al., 2012 Feb 26, Nat NeurosciRead more